| Literature DB >> 35534046 |
Bibek Saha1, Eric Wien2,3, Nicholas Fancher2, Melissa Kahili-Heede2, Nathaniel Enriquez2,3, Alena Velasco-Hughes2,4.
Abstract
OBJECTIVE: Heyde's syndrome (HS), a rare condition characterised by a unique relationship between severe aortic stenosis and angiodysplasia, is often diagnosed late increasing the risk for a prolonged hospital course and mortality in the elderly. The leading hypothesis explaining the aetiology of HS is acquired von Willebrand syndrome (AVWS) but not all studies support this claim. While individual cases of HS have been reported, here we present the first systematic review of case reports and focus on the prevalence of AVWS.Entities:
Keywords: angiodysplasia; diagnostic and therapeutic endoscopy; gastrointestinal bleeding; small bowel enteroscopy
Mesh:
Year: 2022 PMID: 35534046 PMCID: PMC9086603 DOI: 10.1136/bmjgast-2021-000866
Source DB: PubMed Journal: BMJ Open Gastroenterol ISSN: 2054-4774
Figure 1PRISMA flow diagram for search and review strategy. PRISMA, Preferred Reporting Items for Systematic Reviews and Meta-Analyses.
Demographics and risk factors
| n | % | |
| Sex: | ||
| Male | 34 | 44.2 |
| Female | 43 | 55.8 |
| Mean±SD | ||
| Age, all patients (years) | 77 | 74.3±9.3 |
| Age, males (years) | 34 | 73.1±8.5* |
| Age, females (years) | 43 | 75.2±10.0* |
| Aortic valve measurements: | ||
| Area (square cm) | 55 | 0.7±0.3 |
| Peak pressure gradient (mm Hg) | 36 | 93.7±34.0 |
| Mean pressure gradient (mm Hg) | 44 | 56.0±18.6 |
| Peak blood velocity (m/s) | 21 | 4.9±0.8 |
| Severity of valvular disease: | Percentage of total cases (%) | |
| Very severe aortic stenosis (VSAS)† | 32 | 41.6 |
| Severe aortic stenosis (SAS)‡ | 37 | 48.1 |
| Moderate aortic stenosis§ | 3 | 3.9 |
| Severity not stated | 5 | 6.5 |
| Percentage of cases by severity (%) | ||
| VSAS, males | 11 | 34.4* |
| VSAS, females | 21 | 65.6* |
| SAS/moderate, males | 21 | 52.5 |
| SAS/moderate, females | 19 | 47.5 |
| Comorbidities: | Percentage of all comorbidities (%) | |
| Hypertension | 25 | 19.8 |
| Coronary artery disease | 21 | 16.7 |
| Congestive heart failure | 18 | 14.3 |
| Type 2 diabetes mellitus | 12 | 9.5 |
| Atrial fibrillation | 10 | 7.9 |
| Chronic kidney disease | 10 | 7.9 |
| Hyperlipidaemia | 8 | 6.3 |
| History of stroke or TIA | 7 | 5.6 |
| Chronic obstructive pulmonary disease | 6 | 4.8 |
| Obesity | 3 | 2.4 |
| Obstructive sleep apnoea | 2 | 1.6 |
| Primary biliary cholangitis | 2 | 1.6 |
| Thyroid conditions¶ | 2 | 1.6 |
*Within a section, values labelled with a common superscript do not differ (p>0.05).
†VSAS defined by valve area <0.6 cm², mean aortic pressure gradient ≥60 mm Hg and/or peak blood velocity >5 m/s.
‡SAS defined by valve area <1.0 cm², mean aortic valve pressure gradient ≥40 mm Hg and/or peak blood velocity >4 m/s.
§Moderate aortic stenosis defined by valve area 1–1.5 cm², mean aortic valve pressure gradient 20–40 mm Hg and/or peak blood velocity 3–4 m/s.
¶Includes both hyperthyroidism and hypothyroidism.
TIA, transient ischaemic attack.
Gastrointestinal bleed characteristics
| n | % | |
| Source of bleeding identified? | ||
| Yes | 66 | 85.7 |
| No | 10 | 13 |
| No of sources of bleeding* | Percent of total cases identified (%) | |
| 1 | 48 | 62.3 |
| 2 | 12 | 15.6 |
| 3 or more | 5 | 6.5 |
| Source of bleeding location: | ||
| Stomach | 7 | 7.8 |
| Small intestine (unspecified) | 5 | 5.6 |
| Duodenum | 13 | 14.4 |
| Jejunum | 22 | 24.4 |
| Ileum | 11 | 12.2 |
| Small intestine total | 51 | 56.7 |
| Colon (unspecified) | 9 | 10 |
| Cecum | 10 | 11.1 |
| Ascending colon | 10 | 11.1 |
| Transverse colon | 1 | 1.1 |
| Descending colon | 1 | 1.1 |
| Colon total | 31 | 34.4 |
| Rectum | 1 | 1.1 |
| Other sources of bleeding identified† | Percent of other sources identified (%) | |
| Diverticulosis | 4 | 28.6 |
| Gastritis/autoimmune gastritis | 4 | 28.6 |
| Peptic ulcer disease | 2 | 14.3 |
| Bleeding polyp (colonic, gastric) | 2 | 14.3 |
| Other | 2 | 14.3 |
*Number of distinct gastrointestinal bleeding sources identified per patient.
†Gastrointestinal bleeding sources identified other than angiodysplasia or gastric antral vascular ectasia syndrome.
Diagnostics
| Total attempts | Success rate (%) | |
| Diagnostic modalities (GI bleed) | ||
| Gastroscopy | 15 | 26.7 |
| Capsule endoscopy | 30 | 66.7* |
| EGD | 41 | 24.4† |
| Push enteroscopy | 3 | 33.3 |
| DBE | 7 | 85.7* |
| Endoscopy (unspecified) | 11 | 81.8 |
| Colonoscopy | 51 | 31.4† |
| Imaging‡ | 35 | 25.7 |
| n | Mean±SD | |
| No of modalities required to identify bleeding source | 84 | 3.5±1.5 |
| n | Percent of total cases (%) | |
| Evidence of AVWS found§ | 27 | 35.1 |
| Evidence of AVWS not found | 9 | 11.7 |
| AVWS not assessed¶ | 9 | 11.7 |
| AVWS assessment not stated** | 32 | 41.6 |
*†Within a section, values labelled with different superscripts differ (p<0.05), however, values labelled with a common superscript were not compared with one another.
‡Includes angiography, scintigraphy, arteriogram, CT enteroclysis, and barium studies.
§81.5% of these diagnoses were based on gel electrophoresis results.
¶Case reports which stated that they did not assess for AVWS.
**Case reports which did not describe whether or not they assessed for AVWS.
AVWS, acquired von Willebrand syndrome; DBE, double balloon enteroscopy; EGD, oesophagogastroduodenoscopy.
Management and outcomes
| Frequency utilised (%) | Success rate in stopping bleeding (%) | |
| Therapeutic procedure for Heyde’s syndrome: | ||
| SAVR | 49.3 | 92.1* |
| TAVR/TAVI | 24.7 | 84.2* |
| Alternative treatments† | 26 | 45‡ |
| Efficacy of alternative treatments†: | No of times attempted | Success rate in stopping bleeding (%) |
| Balloon aortic valvuloplasty | 3 | 66.7§ |
| Clipping procedure | 7 | 57.1§ |
| Epinephrine injection | 7 | 42.9 |
| Supportive therapy alone | 6 | 33.3 |
| Argon plasma coagulation | 16 | 25§ |
| Cauterisation/coagulation (unspecified) | 9 | 11.1§ |
| Colon/small bowel resection | 7 | 28.6 |
| Octreotide | 4 | 50 |
| Bentall procedure | 1 | 100 |
| Oestrogen | 1 | 0 |
| Desmopressin or vWF supplementation | 2 | 50 |
| Tranexamic acid | 1 | 0 |
| n | Percent of AVWS cases (%) | |
| Resolution of AVWS following treatment | 16 | 59.3 |
*‡§Within a section, values labelled with different superscripts differ (p<0.05), and those with a common superscript do not differ (p>0.05).
†Any treatment not involving valve replacement.
AVWS, acquired von Willebrand syndrome; SAVR, surgical aortic valve replacement; TAVR/TAVI, transcatheter aortic valve replacement/implantation; vWF, von Willebrand factor.